Skip to main content
Fig. 7 | Cancer Nanotechnology

Fig. 7

From: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Fig. 7

Therapeutic efficacy of αCD20/PLD BsAbs in a systemic Raji-tumor SCID mouse model. SCID mice bearing Raji cells were intravenously injected with 2 mg per kg of αCD20/PLD (red, n = 8), αDNS/PLD (blue, n = 7), PLD (green, n = 8), αCD20 BsAb (orange, n = 5) or PBS (black, n = 7). Treatment was performed twice a week for 2 weeks. a Percentage survival as mean and b the mean of body weight were measured every 3 days post-treatment. Bars, SEM. **P < 0.01. *P < 0.05; n.s. not significant

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us